Hidradenitis suppurativa (HS) has a multifactorial etiopathogenesis and is associated with high impairment of quality of life. Empirical findings of increased expression of inflammatory cytokines suggest an immunologic genesis of this inflammatory recurrent skin disease. The range of drug treatments available to date is limited. In parallel with further research into the immunopathological basis, various active substances are being tested in clinical trials.